25412-62-8

Basic information

• Product Name: 3-CHLORO-BENZAMIDINE
• Synonyms: 3-CHLORO-BENZAMIDINE;3-Chlorobenzene-1-carboximidamide;3-Chlorobenzenecarboximidamide;m-Chlorobenzamidine;3-ChlorobenziMidaMide;3-chlorobenziMidaMide hydrochloride;BenzenecarboxiMidaMide, 3-chloro-
• CAS NO: 25412-62-8
• Molecular Formula: C₇H₇ClN₂
• Molecular Weight: 154.6
• Product Categories: pharmacetical
• Mol File: 25412-62-8.mol

Chemical Properties

• Melting Point: 131-133 °C
• Boiling Point: 254.7 °C at 760 mmHg
• Flash Point: 107.8 °C
• Appearance: /
• Density: 1.29
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.597
• Storage Temp.: 2-8°C
• PKA: 11.09±0.50(Predicted)
• CAS DataBase Reference: 3-CHLORO-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-BENZAMIDINE(25412-62-8)
• EPA Substance Registry System: 3-CHLORO-BENZAMIDINE(25412-62-8)

Safety Data

• Hazardous Substances Data: 25412-62-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-Benzamidine is used as an enzyme inhibitor for [application reason], specifically targeting serine proteases. Its ability to inhibit these enzymes makes it a potential candidate for the development of drugs that can interfere with the activity of these enzymes, which are involved in various physiological processes and diseases.
Used in Chemical Research:
3-Chloro-Benzamidine is used as a research compound for [application reason], allowing scientists to study its chemical properties, reactivity, and potential interactions with other molecules. This research can contribute to the development of new chemical processes or the discovery of novel applications for this compound.
Used in Material Science:
3-Chloro-Benzamidine is used as a chemical intermediate for [application reason], potentially serving as a building block in the synthesis of more complex molecules or materials with specific properties. Its unique structure and reactivity may enable the creation of new compounds with applications in various industries, such as electronics or polymers.

InChI:InChI=1/C7H7ClN2/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,(H3,9,10)

Upstream product

• 84738-98-7 amino(methyl)aluminum chloride 
• 766-84-7 3-chloro-benzonitrile 

Downstream Products

• 26863-50-3 2-(3-chloro-phenyl)-1H-pyrimidine-4,6-dione 
• 106690-56-6 2-(3-chlorophenyl)-pyrimidin-4-one 
• 1266522-86-4 4-(3-chlorobenzamidinamide)-2-methyl-5-ethoxy-4-oxazole-4-carbonyl chloride 
• 1431952-05-4 4-(4-bromophenyl)-2-(3-chlorophenyl)-1H-imidazole 
• 1431952-33-8 2-[2-(3-chlorophenyl)-4-(4-hydroxyphenyl)-1H-imidazol-1-yl]-N-(propan-2-yl)acetamide 
• 1431952-32-7 2-{2-(3-chlorophenyl)-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-1-yl}-N-(propan-2-yl)acetamide 

Relevant articles and documents

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS

The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]- pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

CARBOXAMIDE INHIBITORS OF TGFB

Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C- 4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFB activity.

INHIBITORS OF TFGβ

Certain appropriately substituted forms of pyrimidine and triazine are useful in the treatment to conditions associated with enhanced TGFβ activity.